Literature DB >> 23904164

Functional KCa3.1 channels regulate steroid insensitivity in bronchial smooth muscle cells.

Peter Bradding1, Yassine Amrani1, Latifa Chachi1, Aarti Shikotra1, S Mark Duffy1, Omar Tliba2, Christopher Brightling1.   

Abstract

Identifying the factors responsible for relative glucocorticosteroid (GC) resistance present in patients with severe asthma and finding tools to reverse it are of paramount importance. In asthma we see in vivo evidence of GC-resistant pathways in airway smooth muscle (ASM) bundles that can be modeled in vitro by exposing cultured ASM cells to TNF-α/IFN-γ. This action drives GC insensitivity via protein phosphatase 5-dependent impairment of GC receptor phosphorylation. In this study, we investigated whether KCa3.1 ion channels modulate the activity of GC-resistant pathways using our ASM model of GC insensitivity. Immunohistochemical staining of endobronchial biopsies revealed that KCa3.1 channels are localized to the plasma membrane and nucleus of ASM in both healthy controls and asthmatic patients, irrespective of disease severity. Western blot assays and immunofluorescence staining confirmed the nuclear localization of KCa3.1 channels in ASM cells. The functional importance of KCa3.1 channels in the regulation of GC-resistant chemokines induced by TNF-α/IFN-γ was assessed using complementary inhibitory strategies, including KCa3.1 blockers (TRAM-34 and ICA-17043) or KCa3.1-specific small hairpin RNA delivered by adenoviruses. KCa3.1 channel blockade led to a significant reduction of fluticasone-resistant CX3CL1, CCL5, and CCL11 gene and protein expression. KCa3.1 channel blockade also restored fluticasone-induced GC receptor-α phosphorylation at Ser(211) and transactivation properties via the suppression of cytokine-induced protein phosphatase 5 expression. The effect of KCa3.1 blockade was evident in ASM cells from both healthy controls and asthmatic subjects. In summary, KCa3.1 channels contribute to the regulation of GC-resistant inflammatory pathways in ASM cells: blocking KCa3.1 channels may enhance corticosteroid activity in severe asthma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904164      PMCID: PMC3753579          DOI: 10.4049/jimmunol.1300104

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells.

Authors:  O Ghaffar; Q Hamid; P M Renzi; Z Allakhverdi; S Molet; J C Hogg; S A Shore; A D Luster; B Lamkhioued
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

2.  Cytokines alter glucocorticoid receptor phosphorylation in airway cells: role of phosphatases.

Authors:  Belaid Bouazza; Kateryna Krytska; Manel Debba-Pavard; Yassine Amrani; Richard E Honkanen; Jennifer Tran; Omar Tliba
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-16       Impact factor: 6.914

3.  Bronchial thermoplasty for asthma.

Authors:  Gerard Cox; John D Miller; Annette McWilliams; J Mark Fitzgerald; Stephen Lam
Journal:  Am J Respir Crit Care Med       Date:  2006-02-02       Impact factor: 21.405

4.  Calcium-activated potassium channel KCa3.1 in lung dendritic cell migration.

Authors:  Zhifei Shao; Toluwalope O Makinde; Devendra K Agrawal
Journal:  Am J Respir Cell Mol Biol       Date:  2011-04-14       Impact factor: 6.914

5.  Functional KCa3.1 K+ channels are required for human lung mast cell migration.

Authors:  G Cruse; S M Duffy; C E Brightling; P Bradding
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

6.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

7.  Intermediate-conductance Ca2+-activated K+ channel, KCa3.1, as a novel therapeutic target for benign prostatic hyperplasia.

Authors:  Susumu Ohya; Satomi Niwa; Yoshiyuki Kojima; Shoichi Sasaki; Motomu Sakuragi; Kenjiro Kohri; Yuji Imaizumi
Journal:  J Pharmacol Exp Ther       Date:  2011-05-20       Impact factor: 4.030

8.  Voltage-dependent and calcium-activated ion channels in the human mast cell line HMC-1.

Authors:  S M Duffy; M L Leyland; E C Conley; P Bradding
Journal:  J Leukoc Biol       Date:  2001-08       Impact factor: 4.962

Review 9.  Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor.

Authors:  Andrew R Clark; Maria G Belvisi
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

10.  Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms.

Authors:  Elizabeth M King; Joanna E Chivers; Christopher F Rider; Anne Minnich; Mark A Giembycz; Robert Newton
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more
  13 in total

1.  Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors.

Authors:  L Chachi; A Alzahrani; C Koziol-White; M Biddle; R Bagadood; R A Panettieri; P Bradding; Y Amrani
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

2.  Effect of the plant derivative Compound A on the production of corticosteroid-resistant chemokines in airway smooth muscle cells.

Authors:  Adelina Gavrila; Latifa Chachi; Omar Tliba; Christopher Brightling; Yassine Amrani
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

Review 3.  Important lessons learned from studies on the pharmacology of glucocorticoids in human airway smooth muscle cells: Too much of a good thing may be a problem.

Authors:  Yassine Amrani; Reynold A Panettieri; Patricia Ramos-Ramirez; Dedmer Schaafsma; Klaudia Kaczmarek; Omar Tliba
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

4.  Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma.

Authors:  L Chachi; M Abbasian; A Gavrila; A Alzahrani; O Tliba; P Bradding; A J Wardlaw; C Brightling; Y Amrani
Journal:  Allergy       Date:  2016-09-15       Impact factor: 13.146

Review 5.  Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases.

Authors:  Katy M Roach; Peter Bradding
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

6.  The chemokine CX3CL1/fractalkine regulates immunopathogenesis during fungal-associated allergic airway inflammation.

Authors:  Matthew S Godwin; MaryJane Jones; Jonathan P Blackburn; Zhihong Yu; Sadis Matalon; Annette T Hastie; Deborah A Meyers; Chad Steele
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-12-16       Impact factor: 5.464

7.  Orai/CRACM1 and KCa3.1 ion channels interact in the human lung mast cell plasma membrane.

Authors:  S Mark Duffy; Ian Ashmole; Dawn T Smallwood; Mark L Leyland; Peter Bradding
Journal:  Cell Commun Signal       Date:  2015-07-16       Impact factor: 5.712

8.  Developmental conditioning of endothelium-derived hyperpolarizing factor-mediated vasorelaxation.

Authors:  Rebecca Stead; Moji G Musa; Claire L Bryant; Stuart A Lanham; David A Johnston; Richard Reynolds; Christopher Torrens; Paul A Fraser; Geraldine F Clough
Journal:  J Hypertens       Date:  2016-03       Impact factor: 4.844

Review 9.  Insights into glucocorticoid responses derived from omics studies.

Authors:  Mengyuan Kan; Blanca E Himes
Journal:  Pharmacol Ther       Date:  2020-09-08       Impact factor: 12.310

10.  Modulation of Retrograde Trafficking of KCa3.1 in a Polarized Epithelium.

Authors:  Bob Shih-Liang Lee; Daniel C Devor; Kirk L Hamilton
Journal:  Front Physiol       Date:  2017-07-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.